Ushma Wadia

Maternal RSVpreF Vaccine Effectiveness Against Respiratory Syncytial Virus in Hospitalized Infants

Ushma Wadia, Madeline M. Ong, Sarah N. Cox, Huong Le et autres

Importance: In February 2025, Australia introduced maternal vaccination with bivalent respiratory syncytial virus prefusion F protein-based vaccine (RSVpreF) in the National Immunization Program for pregnant individuals from 28 weeks' gestation as the primary, year-round strategy to prevent RSV disease in infants 6 …

au, us (code pays fourni par la source)

Infection Triggered Encephalopathies in Australian Children: A National Multicentre Case Series 2013-2024

Joshua I. Chang, R. C. Dale, Shekeeb Mohammed, Rebecca Burrell et autres

au (code pays fourni par la source)

Safety and immunogenicity of a genetically inactivated stand-alone acellular pertussis vaccine as a booster to Australian adults: a randomized, controlled, non-inferiority trial

Madeline M. Ong, Anita H.J. van den Biggelaar, Leonard Goh, Heidi Hutton et autres

Introduction Waning immunity after acellular pertussis (aP) vaccines shown in pertussis outbreaks highlights the need for more effective aP vaccines. We evaluated the immunogenicity and safety of a stand-alone 2-component aP vaccine (aP 2 ) containing genetically inactivated pertussis toxin (PT) and …

au (code pays fourni par la source)

Empirical Antibiotic Activity and Outcomes in Pediatric Gram-Negative Bloodstream Infections: A Rank-based Composite Outcome Analysis

Sophie C H Wen, Melissa J. Hardy, Abdullah T Aslan, Patrick N A Harris et autres

Background: Timely active empirical therapy (AET) may improve outcomes following bloodstream infection. In high-income settings, low pediatric mortality following gram-negative bloodstream infection (GNBSI) limits its value as a sole endpoint. Composite measures that incorporate multiple clinically relevant outcomes may detect differences more …

Additional file 2 of Optimising COVID-19 episode identification using serology and PCR/rapid antigen testing: insights from the BRACE trial

Ellie McDonald, Laure F. Pittet, Marc Bonten, A Byrne et autres

Supplementary Material 2

au, ch, us, kr, gb, br, es (code pays fourni par la source)

Additional file 1 of Optimising COVID-19 episode identification using serology and PCR/rapid antigen testing: insights from the BRACE trial

Ellie McDonald, Laure F. Pittet, Marc Bonten, A Byrne et autres

Supplementary Material 1

au, ch, us, kr, gb, br, es (code pays fourni par la source)

Additional file 2 of Optimising COVID-19 episode identification using serology and PCR/rapid antigen testing: insights from the BRACE trial

Ellie McDonald, Laure F. Pittet, Marc Bonten, A Byrne et autres

Supplementary Material 2

au, ch, us, kr, gb, br, es (code pays fourni par la source)

Additional file 1 of Optimising COVID-19 episode identification using serology and PCR/rapid antigen testing: insights from the BRACE trial

Ellie McDonald, Laure F. Pittet, Marc Bonten, A Byrne et autres

Supplementary Material 1

au, ch, us, kr, gb, br, es (code pays fourni par la source)

Optimising COVID-19 episode identification using serology and PCR/rapid antigen testing: insights from the BRACE trial.

Ellie McDonald, Laure F. Pittet, Marc Bonten, A Byrne et autres

BACKGROUND: Accurately identifying COVID-19 episodes was crucial during the pandemic for evaluating interventions. Results from diagnostic tools like PCR, rapid antigen test (RAT) and serology are affected by factors such as timing of tests and vaccination status. The BRACE trial developed an …

au (code pays fourni par la source)

Optimising COVID-19 episode identification using serology and PCR/rapid antigen testing: insights from the BRACE trial.

Ellie McDonald, Laure F. Pittet, Marc Bonten, A Byrne et autres

BACKGROUND: Accurately identifying COVID-19 episodes was crucial during the pandemic for evaluating interventions. Results from diagnostic tools like PCR, rapid antigen test (RAT) and serology are affected by factors such as timing of tests and vaccination status. The BRACE trial developed an …

au (code pays fourni par la source)

PICOBOO: the immunogenicity of COVID-19 booster vaccines in individuals >12 years old

Charlie McLeod, Michael Dymock, Katie Flanagan, Magdalena Plebanski et autres

au, gb (code pays fourni par la source)